JERSEY CITY, N.J., July 24, 2019 /PRNewswire/ — SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company delivering innovative therapies for difficult-to-treat and often life-threatening infections, today announced that it has reached an agreement with the U.S. Food and Drug Administration (FDA) under a Special Protocol Assessment (SPA) on the design, trial population, endpoints and statistical analysis of the...
Author: @admin
Summit Highlighted Potential of SMT-571 to Combat the Rising Global Health Threat of Gonorrhoea at STI & HIV World Congress
Summit Therapeutics plc (‘Summit’ or the ‘Company’) Summit Highlighted Potential of SMT-571 to Combat the Rising Global Health Threat of Gonorrhoea at STI & HIV World Congress Oxford, UK, and Cambridge, MA, US, 17 July 2019 – Summit Therapeutics plc (NASDAQ: SMMT, AIM: SUMM) today announced that it highlighted the potential of its preclinical new...
Melinta Therapeutics Announces Preliminary Second Quarter 2019 Financial Results and Provides Corporate Update
~ Expects to Report Second Quarter 2019 Net Product Sales of Approximately $13.8 Million, Which Represents an Increase of 17 Percent Over the First Quarter of 2019 ~ ~ Anticipates Having Approximately $90 Million of Cash and Cash Equivalents on Hand at the End of the Second Quarter 2019 ~ ~ Targeting Full-Year 2019 Operating Expense...
Summit’s DDS-04 Enterobacteriaceae Programme Demonstrates In Vivo Efficacy in Sepsis and Pneumonia
Summit Therapeutics plc (‘Summit’ or the ‘Company’) Summit’s DDS-04 Enterobacteriaceae Programme Demonstrates In Vivo Efficacy in Sepsis and Pneumonia Proof of Concept Now Established in Animal Models Across Key Enterobacteriaceae Indications Pathogen-Targeted Approach Seeks to Preserve Patients’ Microbiomes Oxford, UK, and Cambridge, MA, US, 9 July 2019 – Summit Therapeutics plc (NASDAQ: SMMT, AIM: SUMM)...
World-renowned Fungal Infection Expert Comments on Oral Ibrexafungerp Data Presented by SCYNEXIS at ASM Microbe 2019
JERSEY CITY, N.J., June 25, 2019 /PRNewswire/ — SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company delivering innovative therapies for difficult-to-treat and often life-threatening infections, today announced the availability of nine presentations (here) from the American Society for Microbiology (ASM) Microbe 2019, which occurred June 20-24, 2019, in San Francisco. Ibrexafungerp (formerly SCY-078), the first representative of a...
Nabriva Therapeutics Announces European Medicines Agency (EMA) Validation of Marketing Authorization Application for Lefamulin
DUBLIN, Ireland, June 24, 2019 (GLOBE NEWSWIRE) — Nabriva Therapeutics plc (NASDAQ: NBRV), a clinical-stage biopharmaceutical company engaged in the development of innovative anti-infective agents to treat serious infections, today announced that the European Medicines Agency (EMA) has determined that the Company’s Marketing Authorization Application (MAA) for the intravenous (IV) and oral formulations of lefamulin,...
Iterum Therapeutics to Present Data on Uncomplicated Urinary Tract Infections at ASM Microbe 2019
Limited options remain for successful empiric treatment of uncomplicated urinary tract infections (uUTIs) in the community DUBLIN, Ireland and CHICAGO, June 21, 2019 (GLOBE NEWSWIRE) — Iterum Therapeutics plc (Nasdaq: ITRM), a clinical-stage pharmaceutical company focused on developing next generation antibiotics (oral and IV) to treat infections caused by...
Nabriva Therapeutics to Present Data at ASM Microbe Demonstrating Potential of Lefamulin for Patients with Community-acquired Bacterial Pneumonia (CABP) and CONTEPO™ (fosfomycin) for injection to Treat Complicated Urinary Tract Infections (cUTIs)
DUBLIN, Ireland, June 21, 2019 (GLOBE NEWSWIRE) — Nabriva Therapeutics plc (NASDAQ: NBRV), a clinical-stage biopharmaceutical company engaged in the development of innovative anti-infective agents to treat serious infections, today announced that it will present data at ASM Microbe 2019 to be held June 20 – 24 in San Francisco, CA. “At Nabriva, we are committed to the...
Summit to Present on Pipeline and Strategy for its New Classes of Antibiotics at ASM Microbe 2019
Summit Therapeutics plc (‘Summit’ or the ‘Company’) Summit to Present on Pipeline and Strategy for its New Classes of Antibiotics at ASM Microbe 2019 Oxford, UK, and Cambridge, MA, US, 20 June 2019 – Summit Therapeutics plc (NASDAQ: SMMT, AIM: SUMM) today announced that it will present on its pipeline and strategy for the Company’s...
Melinta Therapeutics Announces U.S. FDA Acceptance of Supplemental New Drug Application for BAXDELA® (delafloxacin) for the Treatment of Community-Acquired Bacterial Pneumonia
~ Application Seeks to Expand Label to Include an Indication and Phase III Data for the Treatment of Adult Patients with Community-Acquired Bacterial Pneumonia (CABP) ~ ~ PDUFA Date Set for October 24, 2019 ~ MORRISTOWN, N.J., June 19, 2019 (GLOBE NEWSWIRE) — Melinta Therapeutics, Inc. (NASDAQ: MLNT), a commercial-stage company focused on the development...